Genetic lesions including focal and recurrent gene deletions or truncating point mutations targeting MGA are enriched in high-risk CLL with chemoresistance and increase the tendency of transformation to an aggressive phenotype[32]. This evidence concerns the gene MGA and B-cell chronic lymphocytic leukemia.